Wall Street Upgrades Two Biotech Stocks: STRO Price Target Tripled, ORIC Now a Buy
Wedbush lifts Sutro to $60 on STRO-004 hopes; ORIC upgraded on strong cancer data and big market potential.
XY Feed↓
/ What's going on?
Filter:
Elliott Management Takes Significant Stake in Dexcom, Pushes for Board Refresh
Dexcom gains Elliott stake; will add board members and restructure, betting on CGM growth; shares rose 6%.
FDA Slaps Full Clinical Hold on Aardvark’s Hunger Drug for Prader-Willi Syndrome
FDA pauses Aardvark’s PWS drug trials over safety concerns; studies stop, shares fall, talks with FDA ongoing.
FDA Fast-Tracks INmune Bio’s XPro for Early Alzheimer’s Disease
FDA gave Fast Track to INmune Bio’s XPro for early Alzheimer’s, speeding trials of a drug targeting brain inflammation.
REGENXBIO Q1 Earnings: Revenue Miss Overshadows Positive Duchenne Gene Therapy Data
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
Biogen Advances Alzheimer’s Drug Diranersen to Phase 3 After It Slashes Tau and Slows Cognitive Decline
Biogen’s diranersen showed robust tau reduction and slowed cognitive decline in early Alzheimer’s Phase 2 trial. Moving to late-stage studies despite missing primary endpoint.
Activist Investor Galloway Capital Takes 8.42% Stake in WW International
WW International rose after Galloway Capital built 8.42% stake, saying company is undervalued despite debt issues.
UBS Turns Bullish on CORT: Lifyorli Expected to Beat Expectations
UBS upgraded CORT to Buy, raised target to $72 on strong Lifyorli cancer drug outlook and steady Korlym sales. Upside ~60–70%.
Zydus Beats Garda with $166 Million All-Cash Takeover of Assertio
Zydus will buy Assertio for $166.4M, paying $23.50/share, giving shareholders more value and taking the company private.
Insider Buying Sends Pulse Biosciences Stock Higher
Pulse Biosciences stock jumped after top executives bought $13M in shares, signaling strong confidence in future growth.
MacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million
MacroGenics sells manufacturing site to Bora for $122.5M, keeps access, gains cash, and focuses on cancer drug development.
Rigel Pharmaceuticals Lands Exclusive Global Deal for Breakthrough Breast Cancer Drug Veppanu
Arvinas & Pfizer partner with Rigel to launch Veppanu, a new oral breast cancer drug showing strong results and better survival.
Hims & Hers Q1 2026 Earnings: Big Subscriber Jump But Misses Estimates – Raises Full-Year Outlook
Hims & Hers missed earnings, lost money, but grew users and expects stronger future growth with higher revenue guidance.
Alpha Tau Reports Breakthrough Interim Results in Brain Cancer Trial: 100% Disease Control and 67% Complete Response
Alpha Tau’s brain cancer trial shows 2/3 glioblastoma patients’ tumors disappeared, all controlled, with good safety so far.
MBX Biosciences Just Took a Big Step Toward Monthly Obesity Injections
MBX drug showed early weight loss up to 7% in 8 weeks, was well tolerated, and may become once-monthly treatment.
Zai Lab’s Zoci Wins U.S. FDA Fast Track Designation for Aggressive Rare Cancer (epNECs)
Zai Lab’s drug Zoci got FDA Fast Track for rare cancer epNEC, showing 38% tumor response in early trials, speeding approval path.
INBRX-106 + Keytruda Nearly Doubles Response Rate in First-Line Head & Neck Cancer
Inhibrx drug INBRX-106 with pembrolizumab boosted tumor response in head/neck cancer, showing higher shrinkage and immune activation.
Coherus Stock Soars on Wall Street Radar: 585% Upside Potential
Guggenheim rates Coherus Oncology Buy with $12 target vs $1.75 now, seeing big upside in cancer drug pipeline but high risk.
Erasca Jumps on Merck Collaboration for RAS-Mutant Cancer Combo Trial
Erasca rises after teaming with Merck to test ERAS-0015 + Keytruda in RAS cancers, showing early tumor shrink but past safety concern.
MoonLake Gets Major Analyst Boost After “Best-in-Class” FDA Meeting
MoonLake gets FDA support for its HS drug, showing top results. Analysts stay bullish with strong growth potential ahead.
Moderna Stock Surges as Hantavirus Vaccine Research Lights Up After Cruise Ship Outbreak
Moderna stock rises as it works on a hantavirus vaccine after a cruise outbreak, but the disease is rare and vaccines will take years.
Replimune Stock Surges After Trump Plans to Fire FDA Chief Marty Makary
Replimune stock jumped after news Trump may fire FDA chief, raising hopes of easier drug approvals despite past rejections.
PTC Therapeutics Beats Wall Street Estimates and Hikes 2026 Outlook on Strong Sephience Launch
PTC beat estimates, Sephience sales surged, losses small, outlook raised, and analysts upgraded stock on strong growth momentum.
Atara Biotherapeutics Stock Soars After FDA Green Light for Cancer Therapy
Atara stock jumps 52% after FDA signals its cancer therapy may get approved, boosting hope for patients and investors.
Why Oppenheimer is Bullish on Tiny Biotech Aprea Therapeutics
Oppenheimer backs Aprea with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential.
Angelini Pharma Buys US Catalyst for $4.1 Billion in State-Backed Deal
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
Dystrophin Miss Sends Entrada Shares Tumbling Despite Functional Win
Entrada DMD drug was safe and helped movement a bit, but low muscle protein results disappointed investors, stock -60%.
enGene Stock Crashes After Bladder Cancer Drug Shows Solid Safety but Disappointing Durability
enGene bladder cancer drug shows good safety and early response, but weak long-term results; stock drops ~66% after update.
Sarepta Therapeutics Q1 2026 Earnings: Big Beat, But Stock Still Falls
Sarepta reported strong Q1 2026 earnings, with revenue of $730.8M, but shares fell as Elevidys sales dropped 46% due to label restrictions.
Oscar Health Just Had Its Most Profitable Quarter Ever
Oscar Health posted record profit, strong growth, and lower costs, showing a major turnaround and fast expansion.
Novavax Smashes Q1 2026 Revenue Expectations with Big Vaccine Tech Deals
Novavax beat forecasts with $140M revenue, boosted by vaccine tech deals, new partnerships, and strong cash position.
CVS Health Raises 2026 Guidance After Strong Q1 Beat and Better Cost Controls
CVS had strong Q1: revenue $100.4B, earnings beat expectations, raised outlook, cash flow up. Stock rose.
Novo Nordisk Raises Full-Year Guidance After Strong Wegovy Pill Launch
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.
Tempus AI Q1 2026: Revenue Beats Expectations, But Stock Drops on Wider Losses
Tempus AI revenue rose 36% to $348M, but losses widened. Stock fell ~7% after weaker profit and cautious outlook.
Avalo Therapeutics Reports Strong Phase 2 Results for Abdakibart in Hidradenitis Suppurativa – Ready to Advance to Phase 3
Avalo’s abdakibart showed strong results in reducing HS symptoms in a Phase 2 trial, with a favorable safety profile and better outcomes than placebo.
Wedbush Ignites Pyxis Oncology with Bullish Rating — 215% Upside Ahead?
Wedbush rates Pyxis “Outperform” with $6 target vs $1.90. Early cancer drug data promising but risky biotech with funding needs.
Cytokinetics’ Myqorzo Succeeds Where Camzyos Failed: Positive Phase 3 Results in Non-Obstructive HCM
Cytokinetics’ (aficamten) met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy (nHCM). Already approved for obstructive HCM, the drug could soon double its market.
Viridian’s Elegrobart Scores Big Win in Chronic Thyroid Eye Disease Phase 3 Trial – Shares Soar
Viridian's drug for thyroid eye disease showed strong Phase 3 results, improving eye symptoms with simple injections and possible home use.
ITK Pipeline Spotlight: Guggenheim Initiates Buy on Aclaris Therapeutics
Guggenheim rates ACRS Buy, $12 target vs $4.50 now; skin/immune drugs, trials ahead, big upside if results are good.
Citizens Bullish on Biomea: Could This Pill Actually Fix Diabetes?
Biomea is testing a new diabetes pill that may fix insulin cells. Early results look strong, with big growth potential but high risk.
UCB Grabs Candid’s BCMA T-Cell Engager – Here’s Why CGEM Investors Are Celebrating
UCB buys Candid Therapeutics for $2B+ to develop immune disease drug that may reset immune system; rivals’ stocks rise.
Mirum’s Volixibat Delivers Major Win in VISTAS Study – First Potential Treatment for Severe Itching in PSC
Mirum’s drug volixibat reduced severe itching in PSC patients in a Phase 2 trial; next step is FDA filing in 2026.
Assertio Shares Jump as Garda Raises All-Cash Buyout Offer to $21.80 Per Share ($153M Deal)
Garda raised bid to $21.80/share cash to buy Assertio, boosting stock ~17%. Deal gives shareholders higher, certain payout.
Eli Lilly Dismisses Foundayo Liver Report as 'Statistical Background Noise' — RBC Maintains Outperform
Eli Lilly states that a post-launch report of hepatic failure for Foundayo (orforglipron) is not plausibly linked to the drug. RBC Capital describes it as “statistical background noise.”
FDA Gives Green Light: Clene’s New ALS Drug Moves Closer to Faster Approval
FDA may fast-track Clene’s ALS drug CNM-Au8 after strong results, offering hope for longer life and slower disease progression.
“Game-Changer” Breast Cancer Drug News Triggers H.C. Wainwright Upgrade for Celcuity
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
FDA Approves First-Ever PROTAC Drug Veppanu for Advanced Breast Cancer with ESR1 Mutation
FDA approved Pfizer/Arvinas Veppanu pill for advanced breast cancer with ESR1 mutation, helping hormone-resistant cases.
Summit Therapeutics Drops 21%: The “Continue” News That Spooked Investors
Summit stock fell after its cancer drug update was just “keep going,” not the big win investors hoped for.
Esperion Stock Surges 57% as ARCHIMED Acquires Company for $1.1 Billion
ARCHIMED will buy Esperion and take it private for $3.16/share (+58% premium) plus up to $100M extra payouts if targets are met.
Moderna Beats Q1 2026 Revenue Estimates as International Sales Surge, Stock Jumps
Moderna beat Q1 revenue on strong overseas COVID vaccine sales, revenue $389M, smaller US demand, reported a per-share loss.
FDA Greenlights AUVELITY: First New Treatment for Alzheimer’s Agitation in Years
FDA approves AUVELITY to treat Alzheimer’s agitation, offering a safer, effective option to reduce distress and improve patient care.
Eli Lilly Crushes Q1 Earnings and Raises 2026 Profit Forecast as Zepbound & Mounjaro Sales Explode
Eli Lilly raised profit outlook thanks to strong Zepbound & Mounjaro sales; revenue and earnings beat expectations, stock rose.
Teva Beats Q1 2026 Forecasts as AUSTEDO & UZEDY Surge — Acquires Emalex for $700M Tourette Drug
Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.
Chiesi Buys KalVista for $1.9 Billion in Biggest Deal Yet to Strengthen Rare Disease Portfolio
Chiesi will buy KalVista for $1.9B to get EKTERLY, a new oral rare disease drug, and grow its global rare disease business.
Humana Beats Q1 2026 Earnings Expectations, Reaffirms Full-Year Adjusted Profit Guidance
Humana beat Q1 2026 expectations, revenue rose, Medicare membership grew, outlook steady but GAAP cut due to lower ratings.
Guggenheim Slaps Buy Rating on CRBP: $45 Target Signals Massive Upside
Corbus Pharmaceuticals gets Buy rating ($45 target). Drug CRB-701 shows strong cancer results, safer than rivals. Stock down 43% may be opportunity.
Guardant Health Shares Fall After FDA Raises Concerns on AstraZeneca Breast Cancer Drug
Guardant stock fell after FDA raised doubts on a key drug study. Delay fears hurt short-term, but long-term outlook still strong.
Pfizer Delays Generic Vyndamax Until 2031 – Great News for BridgeBio’s Attruby
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
Rocket Scores $180 Million Cash Boost – Extends Runway to 2028 for Heart Gene Therapies
Rocket Pharma sold an FDA voucher for $180M cash, boosting funds without dilution and extending runway to 2028 for heart gene therapies.
Erasca Stock Crashes on Patient Death — But Analysts Call the Selloff Overdone
Erasca stock fell after a patient died in a cancer drug trial. Analysts say it’s likely a rare case, drug still shows promise.
HyBryte Skin Cancer Drug Fails Key Test – Soligenix FLASH2 Trial Halted
Soligenix stopped HyBryte CTCL trial early as it didn’t work well, though it was safe; company will review data and options.
Catalyst Pharmaceuticals Stock Surges on Angelini Pharma Buyout Rumors
Angelini Pharma may buy Catalyst Pharmaceuticals. Talks are early, but news pushed Catalyst’s stock up. No deal is certain yet.
Craig-Hallum Initiates Strong Buy on Spruce Biosciences with $140 Price Target as TA-ERT Advances Toward Approval
Spruce Biosciences has a rare disease drug (TA-ERT) showing strong results, FDA path clear, big sales and upside potential.
Erasca Vows to Fight Revolution Medicines Patent Allegations – Stifel Stays Bullish
Erasca denies patent claims by Revolution Medicines, will fight back; Stifel keeps Buy rating.
PFS Triumph or OS Flop? Why CMPX Shares Plunged Despite Positive Cancer Results
Compass Therapeutics fell after cancer drug improved outcomes but failed to show clear survival benefit due to patient crossover.
Veradermics’ Oral Hair Loss Pill Scores Major Win in Late-Stage Trial
Veradermics’ hair pill VDPHL01 showed strong results, growing 30+ hairs/cm in trials, safe, and may become a new baldness treatment.
Oruka’s Long-Acting Psoriasis Drug Hits 63.5% Complete Skin Clearance in Mid-Stage Trial
Oruka’s new psoriasis drug cleared skin in most patients with few side effects and may need only yearly injections.
Eli Lilly Acquires Ajax Therapeutics to Advance New Treatment for Rare Blood Cancers
Eli Lilly buys Ajax to develop a new pill for rare blood cancers that may work longer and better than current treatments.
Ligand Buys Xoma for $740M, Doubling Its Drug Royalty Portfolio
Ligand buys Xoma for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk.
Sun Pharma Acquires Organon in $11.75 Billion Deal – India’s Biggest Overseas Pharma Buy
Sun Pharma will buy Organon for $11.75B, boosting global reach, women’s health, and specialty drugs, and creating a $12.4B annual revenue pharma giant.
Deutsche Bank and Truist Go Bullish on Ascentage Pharma
Ascentage Pharma gets Buy ratings; its cancer drugs show strong results, fast growth in China, and high future upside potential.
Radoff-JEC Group Boosts Seer Takeover Bid to $2.35
Investors offered to buy Seer for $2.35/share plus extra future payout; stock rose after takeover bid. Board responds by May 2.
Lilly’s New Weight-Loss Pill Foundayo Gets Off to a Slow Start
Lilly’s new weight-loss pill started slow, far behind Novo’s, but it’s too early to tell which drug will win.
Indian Pharma Giant Sun Pharma Launches $13 Billion Takeover Bid for Organon
Sun Pharma offers $13B to buy Organon, aiming to expand globally in branded drugs, competing with EQT and Grünenthal.
Oppenheimer Turns Bullish on Savara as Molgramostim Moves Closer to Approval
Savara gets FDA priority review for its drug, analyst raises target to $11, sees strong approval chances and upside.
JPMorgan Gives Hims & Hers a $35 Bullish Rating – Full GLP-1 Lineup Just Got Even Stronger
JPMorgan backs Hims & Hers Health as a strong buy, boosted by GLP-1 drugs and big deals with Novo Nordisk and Eli Lilly.
Cannabis Stocks Drop After Early Surge on Limited US Marijuana Rescheduling Move
Cannabis stocks fell after hype faded: US reform helps medical marijuana only, not full market, so investors took profits.
Regeneron Strikes Deal with Trump: Free Gene Therapy for Hearing Loss + Lower Drug Prices for Americans
Regeneron will cut U.S. drug prices, offer free gene therapy for hearing loss, and align costs with other countries under a Trump deal.
Grace Therapeutics Gets FDA Feedback on GTx-104: No New Clinical Trials Needed, Resubmission Planned
FDA flagged fixable issues for GTx-104, not rejection. No new trials needed. IV drug may improve brain bleed ICU treatment.
OpenAI’s Free ChatGPT for Doctors Triggers Doximity Stock Slide
OpenAI launched ChatGPT for doctors to help with notes and research. It’s free in the US, boosts AI use, and Doximity stock fell.
IKS Health Acquires TruBridge to Boost Rural Healthcare Access
IKS Health is buying TruBridge to improve rural US healthcare using AI. Deal helps 2000 hospitals, closes 2026.
Trump Administration Set to Reclassify Marijuana This Week
The Trump administration is expected to reclassify marijuana from Schedule I to Schedule III as soon as this week, easing research barriers after months of delay.
Amneal Acquires Kashiv BioSciences in $1.1B Deal to Ride $300 Billion Biosimilar Wave
Amneal is buying Kashiv BioSciences for up to $1.1 billion to become a global leader in affordable biosimilar drugs. Strong Q1 results beat expectations and 2026 guidance raised.
$8 Billion Opportunity: Inhibrx’s Experimental Cancer Drug Draws Major Interest
Inhibrx is drawing strong interest from Merck and other big pharma for its experimental cancer drug INBRX-106 that could boost Keytruda. Potential $9B spin-off value.
Kyverna’s miv-cel Scores Historic Win in Stiff Person Syndrome – First CAR-T Poised for FDA Approval
Kyverna’s CAR-T drug greatly improved rare SPS: patients walked 46% faster, many stopped meds; FDA filing planned 2026.
CVC and GTCR Team Up to Take Medical Device Maker Teleflex Private
Private equity firms CVC Capital Partners and GTCR have submitted a joint offer to take medical device company Teleflex (TFX) private. Shares jumped on the news.
Merck and Eisai Phase 3 Miss Shakes Up Kidney Cancer Race – Analysts Split on Arcus
Merck’s new kidney cancer combos failed in Phase 3, missing key goals; analysts see mixed impact for Arcus and its drug.
Citi: Amazon’s Cheap GLP-1 Renewals Could Hurt Hims — But Not Replace It
Citi analysts say Amazon One Medical’s new $29 on-demand GLP-1 prescription renewals could pressure Hims & Hers, but they are not a full replacement for the telehealth weight-loss giant.
Mizuho Upgrades Outlook: Harmony’s Wakix Now Protected Until 2030
Harmony Biosciences wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target.
Ionis’ Zilganersen Stabilizes Walking and Motor Skills in Alexander Disease Study
Ionis drug zilganersen showed promise for rare brain disease (Alexander disease), improving symptoms; FDA decision due Sept 2026.
Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
UnitedHealth Group Beats Q1 2026 Expectations and Raises Full-Year Profit Outlook
UnitedHealth Group beat expectations, raised outlook, cut costs, and grew steadily—showing a solid turnaround and boosting investor confidence.
Wall Street Backs Achieve Life Sciences: Cytisinicline Labeled 'Best-in-Class' Smoking Cessation Drug
Achieve Life Sciences gets Buy rating as its quit-smoking drug cytisinicline shows strong results; FDA decision due June 2026.
BBOT Scores FDA Fast Track for BBO-11818: A New Targeted Therapy for KRAS-Mutant Pancreatic Cancer
BBOT receives U.S. FDA Fast Track Designation for BBO-11818, its pan-KRAS inhibitor for advanced KRAS-mutant pancreatic cancer. Phase 1 data expected H2 2026.
Arcus Biosciences Stops Phase 3 STAR-121 Lung Cancer Trial and Updates Gilead Partnership
Arcus stops a lung cancer trial early after poor outlook, ends a partner study, and gains more control as Gilead scales back the deal.
Cantor Fitzgerald Calls Candel Therapeutics Deeply Undervalued – Overweight Rating Initiated
Cantor is very bullish on CADL, sees big undervaluation and CAN-2409 as a major drug with huge growth potential.
Agios Pharma Shares Crash as Novo Nordisk Posts Strong Phase 3 Sickle Cell Results
Novo Nordisk’s new pill cuts sickle cell pain crises, boosting outcomes and sending Agios Pharma shares down after strong trial results.
New Drug Shows Stronger Hair Regrowth After 1 Year in Severe Alopecia Areata
Nektar drug showed promising hair regrowth in severe alopecia areata after 52 weeks, with good safety and twice-monthly shots.
Passage Bio Stock Plunges as FDA Demands Full Randomized Trial for PBFT02
Passage Bio fell after the FDA demanded a larger trial; the drug shows promise for brain disease, but its future is now costlier and slower.
Perspective Therapeutics Shares Positive 2026 Trial Update – 43% Response Rate in Advanced Neuroendocrine Tumors
New alpha therapy for advanced NETs shows good safety and early tumor shrinkage in ~43% patients, with encouraging results so far.